GYNECOLOGIC CANCER: Edited by Gottfried E. KonecnyNew clinical research strategies for rare gynecologic malignanciesRay-Coquard, Isabellea; Pujade-Lauraine, Ericb; Ledermann, Jonathan A.c Author Information aDepartment of Adult Medical Oncology, Centre Leon Berard, Université Claude Bernard, Lyon bHôpital Hôtel-Dieu, AP-HP, Université Paris Descartes, Paris, France cUCL Cancer Institute, London, UK Correspondence to Prof Isabelle Ray-Coquard MD, PhD, Department of Adult Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France. E-mail: [email protected] Current Opinion in Obstetrics and Gynecology: February 2015 - Volume 27 - Issue 1 - p 53-57 doi: 10.1097/GCO.0000000000000144 Buy Metrics Abstract Purpose of review More than 50% of all gynecologic cancers can be classified as rare tumors (defined as an incidence of <6 per 100 000) and as such represent a major challenge for clinicians. Recent findings The rapidly increasing number of targeted therapies provides a unique opportunity to improve treatment options of rare gynecologic cancers; however, their low frequency makes it difficult to test these new agents. Harmonization of medical practices and novel trial designs are needed to identify and develop new treatments for rare gynecologic tumors. Summary This requires international partnerships, harmonization of treatment recommendations, and international collaborations to overcome existing regulatory barriers in international trials. Whereas randomized trials may be possible in some rare tumor types, there are others for which conducting even single arm studies may be challenging. For these very rare tumors, robust collection of data through national registries could lead to improvements in treatment. Copyright © 2015 YEAR Wolters Kluwer Health, Inc. All rights reserved.